Matches in SemOpenAlex for { <https://semopenalex.org/work/W96323974> ?p ?o ?g. }
- W96323974 endingPage "297" @default.
- W96323974 startingPage "290" @default.
- W96323974 abstract "The purpose of this study was to test the safety and efficacy of pioglitazone and simvastatin in combination versus each drug individually in non-diabetic subjects with cardiovascular disease (CVD) and elevated high-sensitivity C-reactive protein (hs-CRP) levels.Low-grade inflammation is a pathogenic factor for atherosclerosis. High-sensitivity CRP, matrix metalloproteinase (MMP)-9, and plasminogen activator inhibitor (PAI)-1 are markers of inflammation. Statins and peroxisome proliferator-activated receptor (PPAR)-gamma agonists lower inflammatory markers and reduce CVD in type 2 diabetes.In a 12-week, prospective, double-blind trial, 125 subjects were randomized to simvastatin or pioglitazone plus placebo or a simvastatin/pioglitazone combination. We tested changes in hs-CRP by analysis of covariance. A subgroup analysis was performed in patients with and without the metabolic syndrome (MetS). The correlation between changes in hs-CRP and homeostasis model assessment (HOMA; a measure of insulin resistance) was calculated with the Spearman's rank test.At baseline, there were no significant between-group differences. At 12 weeks, pioglitazone and simvastatin monotherapies significantly reduced hs-CRP (3.64 +/- 2.42 mg/l to 2.48 +/- 1.77 mg/l and 3.26 +/- 2.02 mg/l to 2.81 +/- 2.11 mg/l) and the combination regimen had an additive effect (from 3.49 +/- 1.97 mg/l to 2.06 +/- 1.42 mg/l, p < 0.001). For subgroups, the difference between monotherapy and combination therapy was only significant for simvastatin versus simvastatin plus pioglitazone in patients without MetS. Homeostasis model assessment decreased in those receiving pioglitazone, and the correlation between changes in HOMA and hs-CRP was significant (r = 0.43; p < 0.05). The PAI-1 decreased significantly in the pioglitazone groups only, and MMP-9 was also significantly lowered in the pioglitazone groups. No treatment-related serious adverse events occurred in any group.Pioglitazone, probably by reducing insulin resistance, has additive anti-inflammatory effects to simvastatin in non-diabetic subjects with CVD and high hs-CRP." @default.
- W96323974 created "2016-06-24" @default.
- W96323974 creator A5015300055 @default.
- W96323974 creator A5019976194 @default.
- W96323974 creator A5022402496 @default.
- W96323974 creator A5024533360 @default.
- W96323974 creator A5044130587 @default.
- W96323974 creator A5044778195 @default.
- W96323974 creator A5052329017 @default.
- W96323974 creator A5066562800 @default.
- W96323974 date "2007-01-01" @default.
- W96323974 modified "2023-09-23" @default.
- W96323974 title "Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein" @default.
- W96323974 cites W174705705 @default.
- W96323974 cites W1968973887 @default.
- W96323974 cites W1983501278 @default.
- W96323974 cites W1984578167 @default.
- W96323974 cites W1992834760 @default.
- W96323974 cites W2008674682 @default.
- W96323974 cites W2014113220 @default.
- W96323974 cites W2041244472 @default.
- W96323974 cites W2058610272 @default.
- W96323974 cites W2058709767 @default.
- W96323974 cites W2060351304 @default.
- W96323974 cites W2078183606 @default.
- W96323974 cites W2082953097 @default.
- W96323974 cites W2085677782 @default.
- W96323974 cites W2087287221 @default.
- W96323974 cites W2089044080 @default.
- W96323974 cites W2094083143 @default.
- W96323974 cites W2095647681 @default.
- W96323974 cites W2101198954 @default.
- W96323974 cites W2102469433 @default.
- W96323974 cites W2102899779 @default.
- W96323974 cites W2103714496 @default.
- W96323974 cites W2111184067 @default.
- W96323974 cites W2112546342 @default.
- W96323974 cites W2118154631 @default.
- W96323974 cites W2121037015 @default.
- W96323974 cites W2124120680 @default.
- W96323974 cites W2126026626 @default.
- W96323974 cites W2128899850 @default.
- W96323974 cites W2129750583 @default.
- W96323974 cites W2132440468 @default.
- W96323974 cites W2142179136 @default.
- W96323974 cites W2143991719 @default.
- W96323974 cites W2145053304 @default.
- W96323974 cites W2155598961 @default.
- W96323974 cites W2159969745 @default.
- W96323974 cites W2164367541 @default.
- W96323974 cites W2165815833 @default.
- W96323974 cites W2316376271 @default.
- W96323974 cites W2322095705 @default.
- W96323974 cites W287423398 @default.
- W96323974 cites W38523360 @default.
- W96323974 cites W4244213849 @default.
- W96323974 doi "https://doi.org/10.1016/j.jacc.2006.08.054" @default.
- W96323974 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17239709" @default.
- W96323974 hasPublicationYear "2007" @default.
- W96323974 type Work @default.
- W96323974 sameAs 96323974 @default.
- W96323974 citedByCount "153" @default.
- W96323974 countsByYear W963239742012 @default.
- W96323974 countsByYear W963239742013 @default.
- W96323974 countsByYear W963239742014 @default.
- W96323974 countsByYear W963239742015 @default.
- W96323974 countsByYear W963239742016 @default.
- W96323974 countsByYear W963239742017 @default.
- W96323974 countsByYear W963239742018 @default.
- W96323974 countsByYear W963239742019 @default.
- W96323974 countsByYear W963239742020 @default.
- W96323974 countsByYear W963239742021 @default.
- W96323974 countsByYear W963239742022 @default.
- W96323974 countsByYear W963239742023 @default.
- W96323974 crossrefType "journal-article" @default.
- W96323974 hasAuthorship W96323974A5015300055 @default.
- W96323974 hasAuthorship W96323974A5019976194 @default.
- W96323974 hasAuthorship W96323974A5022402496 @default.
- W96323974 hasAuthorship W96323974A5024533360 @default.
- W96323974 hasAuthorship W96323974A5044130587 @default.
- W96323974 hasAuthorship W96323974A5044778195 @default.
- W96323974 hasAuthorship W96323974A5052329017 @default.
- W96323974 hasAuthorship W96323974A5066562800 @default.
- W96323974 hasBestOaLocation W963239741 @default.
- W96323974 hasConcept C126322002 @default.
- W96323974 hasConcept C134018914 @default.
- W96323974 hasConcept C142724271 @default.
- W96323974 hasConcept C204787440 @default.
- W96323974 hasConcept C27081682 @default.
- W96323974 hasConcept C2776329913 @default.
- W96323974 hasConcept C2776914184 @default.
- W96323974 hasConcept C2777180221 @default.
- W96323974 hasConcept C2777391703 @default.
- W96323974 hasConcept C2778384471 @default.
- W96323974 hasConcept C2781195455 @default.
- W96323974 hasConcept C555293320 @default.
- W96323974 hasConcept C71924100 @default.
- W96323974 hasConcept C90924648 @default.